ECNU researchers with the Shanghai Key Laboratory of Regulatory Biology and the Key Laboratory of Adolescent Health Assessment and Exercise Intervention of the Ministry of Educationhave made a major breakthrough in the research of bone growth and height.
Researchers have unraveled that The Gpr126/Adgrg6 is associated with body height. Their study explored a potential cure for short stature in adolescents. This might offer a solution to short stature caused by Gpr126/Adgrg6-related gene mutation, which has been a major problem for scientists worldwide.
An article on the finding was published in Science on March 20, 2020, under the title "Regulation of body length and bone mass by Gpr126/Adgrg6."
The correspondent authors of the study are Prof. Liu Mingxiao and Luo Jian with the Shanghai Key Laboratory of Regulatory Biology, and Prof. Su Jiacan with Changhai Hospital Affiliated to the Second Military Medical University. The first authors are associate professor Sun Peng with the Key Laboratory of Adolescent Health Assessment and Exercise Intervention of the Ministry of Education and He Liang, a doctoral student of ECNU’s School of Life Sciences.
After conducting a series of in vivo and in vitro experiments, the researchers found Teriparatide, a biosynthetic human parathyroid hormone (PTH 1–34), which is used to treat osteoporosis and which can effectively improve the phenotype of the shortening caused by the absence of Gpr
They also discovered that PTH（1-34) can greatly stimulate osteoblast proliferation and differentiation while increasing the status of bone strength, bone mass and bone mineral density.
This study intends to provide a solution to the hot topic of precision treatment for height dwarfism caused by Gpr126/Adgrg6-related gene mutation in teenagers.
The research project was funded by some of China’s top research foundations including the National Key Research and Development Project, and the Key Program of National Natural Science Foundation.
Source: The School of Life Science
Copy editor: Joshua Mayfield
Editor: Yu Wenxi